-9999
Floor Speech
BREAK IN TRANSCRIPT
Mr. CARSON. Mr. Speaker, I rise today in support of the National Defense Authorization Act (NDDA) and my bipartisan amendment which authorizes an increase of five million dollars for a pancreatic cancer early detection initiative (EDI) at the Department of Defense (DoD). I thank my colleagues, Rep. Eshoo and Rep. McKinley, for their support and leadership on this issue. Pancreatic cancer has the lowest survival rate of all major cancers--in large part due to lack of research in early detection. I believe we all agree that the patients, families, friends and loved ones suffering from this disease deserve greater support.
My amendment will provide critical funding needed for more research and an early detection initiative under the Congressionally Directed Medical Research Programs (CDMRP) at DoD. I was pleased that the Appropriations Defense Subcommittee appropriated fifteen million dollars for general pancreatic cancer research funding in this year's funding legislation. While encouraging, we need to continue doing more and should increase funding to twenty million dollars in FY23.
This issue has hit painfully close to home recently, as America lost giants to pancreatic cancer. Rep. John Lewis, our civil rights hero, passed away from pancreatic cancer only seven months after receiving his diagnosis. My good friend and colleague, Rep. Alcee Hastings, also passed from Pancreatic Cancer last year. And, Americans lost a fighter for voting rights and women's protection, Justice Ruth Bader Ginsburg, to this deadly disease. And Alex Trebek, who was welcomed into people's homes around the world, lost his battle to pancreatic cancer in 2020. We have lost too many loved ones and must do everything we can to save lives. It is unacceptable that, despite being the third leading cause of cancer-related death in our country, pancreatic cancer still does not have a dedicated early detection initiative. In fact, the lack of research in ways to detect pancreatic cancer early has led to devastating consequences: sixty-six percent of patients live less than one year following their diagnosis.
If diagnosed early, the five-year survival rate for pancreatic cancer patients is above eighty percent. However, if pancreatic cancer is detected late, the five-year survival rate drops to less than five percent. By failing to support our nation's researchers with the means to find new ways to detect pancreatic cancer early, we are leaving America's pancreatic cancer patients with few ways to detect this disease in time to extend the quality and duration of their lives.
It's important to note that persistent health care inequities and disparities for communities of color compound the devastation of pancreatic cancer and the effects of lack of early detection research. Unfortunately, Black people are more likely than their fellow Americans to get pancreatic cancer. In fact, the incidence rate for pancreatic cancer among Black Americans is twenty percent higher than any other racial demographic. This disease is more deadly for us: the pancreatic cancer death rate is seventeen percent higher for Black men than white men. Significant evidence demonstrates that these disproportionate levels of pancreatic cancer are in large part rooted in disparities in health care and access to tests and diagnostics. As a result, the lack of pancreatic cancer early detection research accelerates the racial unfairness in our health care system, with devastating consequences for minorities.
At a time when our country is having a national conversation about the deep disparities in access to health care for Black and Brown people during a global pandemic, Congress must do everything within our power to improve health outcomes through research and treatment. Increasing dedicated funding for early detection research at DoD will help fill a critical gap in our pancreatic cancer research and will help address the pancreatic cancer disparities for communities of color.
I urge the House to support this amendment.
BREAK IN TRANSCRIPT
Source